Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 3/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cloperastine SCHEMBL9613613 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP3A4CYP1A2 | |
| Cloperastine SCHEMBL284715 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP3A4CYP1A2 | |
| Cloperastine SCHEMBL23733 | 0.99 | CYP3A4 (1.00) | SLC6A2SLC6A4SLC6A3CYP3A4CYP1A2 | |
| SCHEMBL1151981 | 0.99 | SLC6A2 (0.97) | SLC6A2SLC6A4SLC6A3CYP3A4CYP1A2 | |
| Cloperastine SCHEMBL1651228 | 0.97 | SLC6A2 (0.95) | SLC6A2SLC6A4SLC6A3CYP3A4CYP1A2 | |
| Perastine SCHEMBL1506306 | 0.91 | CYP3A4 (0.83) | SLC6A2SLC6A4SLC6A3CYP3A4CYP1A2 | |
| Perastine SCHEMBL29768269 | 0.90 | CYP3A4 (0.83) | SLC6A2SLC6A4SLC6A3CYP3A4CYP1A2 | |
| SCHEMBL9050633 | 0.86 | SIGMAR1 (0.84) | SLC6A2SLC6A4SLC6A3CYP3A4CYP1A2 | |
| Difencloxazine SCHEMBL29710921 | 0.86 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3CYP3A4CYP1A2 | |
| SCHEMBL17942915 | 0.86 | CYP3A4 (0.75) | SLC6A2SLC6A4SLC6A3CYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3644968-B1 | LEVOCLOPERASTINE FENDIZOATE SUSPENSION HAVING ENHANCED DISSOLUTION AND RESUSPENDABILITY | ILKO ILAC SANAYI VE TICARET ANONIM SIRKETI (TR) | 2025-01-08 | — | — | EP | claimed |
| US-20230390271-A1 | ANTI-VERTIGO COMPOUND AND PHARMACEUTICAL COMPOSITIONS THEREOF | AMNEAL PHARMACEUTICALS LLC | 2023-12-07 | — | — | US | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| EP-3644968-B1 | LEVOCLOPERASTINE FENDIZOATE SUSPENSION HAVING ENHANCED DISSOLUTION AND RESUSPENDABILITY | ILKO ILAC SANAYI VE TICARET ANONIM SIRKETI (TR) | 2025-01-08 | — | — | EP | disclosed |
| EP-3644968-B1 | LEVOCLOPERASTINE FENDIZOATE SUSPENSION HAVING ENHANCED DISSOLUTION AND RESUSPENDABILITY | ILKO ILAC SANAYI VE TICARET ANONIM SIRKETI (TR) | 2025-01-08 | — | — | EP | disclosed |
| EP-4299059-A1 | COMPOSITION FOR THE TREATMENT OF TINNITUS | Labelic Analysis, S.L. (ES) | 2024-01-03 | — | — | EP | disclosed |
| US-20230390271-A1 | ANTI-VERTIGO COMPOUND AND PHARMACEUTICAL COMPOSITIONS THEREOF | AMNEAL PHARMACEUTICALS LLC | 2023-12-07 | — | — | US | disclosed |
| US-20230390271-A1 | ANTI-VERTIGO COMPOUND AND PHARMACEUTICAL COMPOSITIONS THEREOF | AMNEAL PHARMACEUTICALS LLC | 2023-12-07 | — | — | US | disclosed |
| WO-2022091118-A1 | ANTI-VERTIGO COMPOUND AND PHARMACEUTICAL COMPOSITIONS THEREOF | AMERISE PHARMACEUTICALS PVT LTD. (IN) | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230390271-A1 | ANTI-VERTIGO COMPOUND AND PHARMACEUTICAL COMPOSITIONS THEREOF | VDAC3, HRH2, VDAC2 | SLC6A2 629/4885SLC6A4 936/4885SLC6A3 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.